← Back to Search
Claudin‐4 Immunohistochemistry Is Highly Effective In Distinguishing Adenocarcinoma From Malignant Mesothelioma In Effusion Cytology
V. Jo, E. Cibas, G. Pinkus
Published 2014 · Medicine
Download PDFAnalyze on Scholarcy
Adenocarcinoma can be challenging to distinguish from malignant mesothelioma in effusions, and this distinction often requires ancillary studies and clinical correlation. Immunohistochemistry for claudin‐4, a tight‐junction‐associated protein, has recently been shown to distinguish adenocarcinoma from malignant mesothelioma, mostly in surgical specimens. Our aim was to validate and assess the immunoreactivity profile of claudin‐4 in a large series of malignant effusions.
This paper references
Claudin Family of Proteins and Cancer: An Overview
A. B. Singh (2010)
Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcoma.
A. Sandberg (2004)
Parakeratotic-like cells in effusions — A clue to diagnosis of malignant mesothelioma
L. Gao (2012)
The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study
N. Ordóñez (2006)
Application of immunohistochemistry to the diagnosis of malignant mesothelioma.
A. Marchevsky (2008)
A Comprehensive Analysis of PAX8 Expression in Human Epithelial Tumors
Anna R. Laury (2011)
Value of PAX8, PAX2, napsin A, carbonic anhydrase IX, and claudin-4 immunostaining in distinguishing pleural epithelioid mesothelioma from metastatic renal cell carcinoma
N. Ordóñez (2013)
Markers for metastatic adenocarcinoma in serous effusion specimens
P. Shield (1994)
Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions
D. Chhieng (2000)
Value of claudin-4 immunostaining in the diagnosis of mesothelioma.
N. Ordóñez (2013)
Calretinin staining pattern
Claudins: unlocking the code to tight junction function during embryogenesis and in disease
I. Gupta (2010)
The diagnostic and prognostic utility of claudin expression in renal cell neoplasms
Mirna Lechpammer (2009)
Diagnostic value of monoclonal antibody B72.3 in detecting adenocarcinoma cells in serous effusions
A. F. Lauritzen (1989)
Usefulness of Claudin 4 in the cytological diagnosis of serosal effusions
S. Lonardi (2011)
Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura
Y. Soini (2006)
Evidence-based Guidelines for the Utilization of Immunostains in Diagnostic Pathology: Pulmonary Adenocarcinoma Versus Mesothelioma
A. Marchevsky (2007)
Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity
H. Yaziji (2006)
Comparison of antibodies to HBME‐1 and calretinin for the detection of mesothelial cells in effusion cytology
P. Fetsch (2001)
Cytogenetics and fluorescence in situ hybridization as adjuncts to cytology in the diagnosis of malignant mesothelioma
Rachel E. Factor (2009)
The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions
P. Shield (2008)
Monoclonal antibody Ber‐EP4: Its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens
B. Maguire (1994)
Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1.
M. E. Bailey (1996)
Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions
F. Facchetti (2007)
Claudin Expression in High Grade Invasive Ductal Carcinoma of the Breast: Correlation with the Molecular Subtype
Shaolei Lu (2013)
Immunocytochemistry in the differential diagnosis of effusions: use of logistic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations.
D. Frisman (1993)
Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Mesothelioma.
A. Sandberg (2001)
Thyroid Transcription Factor-1: A Review
S. Lau (2002)
Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas
N. Ordóñez (2013)
M. Lal-Nag (2009)
Utility of WT‐1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions
Robert T. Pu (2008)
Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology?
Virganeyce Lyons-Boudreaux (2008)
CDX2, a Highly Sensitive and Specific Marker of Adenocarcinomas of Intestinal Origin: An Immunohistochemical Survey of 476 Primary and Metastatic Carcinomas
Robert W Werling (2003)
PAX8 Reliably Distinguishes Ovarian Serous Tumors From Malignant Mesothelioma
Anna R. Laury (2010)
The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions: the role of routine mucin histochemistry and immunohistochemical assessment of carcinoembryonic antigen, keratin proteins, epithelial membrane antigen, and milk fat globule-derived antigen.
E. Cibas (1987)
Claudin-4 Expression Predicts Survival in Pancreatic Ductal Adenocarcinoma
K. Tsutsumi (2011)
Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
N. Ordóñez (1998)
Claudin‐4 in mesothelioma diagnosis
F. Facchetti (2007)
This paper is referenced by
The diagnostic role of PTEN and ARID1A in serous effusions
B. Davidson (2017)
Utility of Claudin-4 versus BerEP4 and B72.3 in pleural fluids with metastatic lung adenocarcinoma.
Ami Patel (2020)
Claudin-4 Shows Superior Specificity for Mesothelioma vs Non-Small Cell Lung Carcinoma Compared to MOC-31 and Ber-EP4.
Julia R Naso (2020)
P16 as a marker of carcinoma in effusions and peritoneal washing
Fabiana Pirani Carneiro (2020)
Cytology of Pleural and Peritoneal Lesions
Shikha Bose (2018)
Reliability of p-16, calretinin, and claudin-4 immunocytochemistry in diagnostic verification of effusion cytology
Eman S. Abusinna (2019)
CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells.
B. Davidson (2016)
Biomarkers for pancreatic cancer : identification, validation and clinical application
Asif Ali (2015)
Serous cavity fluids: Momentum, molecules, markers… and more!
Momin T Siddiqui (2020)
Application of immunohistochemistry in diagnosis and management of malignant mesothelioma.
D. Chapel (2020)
Transcriptomic Analysis of the Claudin Interactome in Malignant Pleural Mesothelioma: Evaluation of the Effect of Disease Phenotype, Asbestos Exposure, and CDKN2A Deletion Status
E. Rouka (2017)
BIBLIOGRAPHIC REVIEW July 2016 Third Consensus Conference on Malignant Pleural Mesothelioma: State-of-the-art and recommendations
Epithelial cell adhesion molecule (EpCAM) from pleural fluid cell lysates is a highly accurate diagnostic biomarker of adenocarcinomatous effusions
J. M. Porcel (2019)
Diagnostic Accuracy of Calretinin for Malignant Mesothelioma in Serous Effusions: a Meta-analysis
Diandian Li (2015)
Signet ring cell mesothelioma; A diagnostic challenge.
Hui Wang (2019)
Investigating Various Thresholds as Immunohistochemistry Cutoffs for Observer Agreement
Asif Ali (2017)
Diagnostic Usefulness of Claudin-3 and Claudin-4 for Immunocytochemical Differentiation between Metastatic Adenocarcinoma Cells and Reactive Mesothelial Cells in Effusion Cell Blocks
N. I. Kim (2016)
Chapter 12 – Pericardial Disease and Effusion
D. Lotan (2016)
Diagnostic Value of the EZH2 Immunomarker in Malignant Effusion Cytology
Piao Piao Ang (2019)
Claudin‐4 immunohistochemistry is a useful pan‐carcinoma marker for serous effusion specimens
Melissa Vojtek (2019)
A case of malignant mesothelioma pleural effusion with MOC‐31, BerEP4, and calretinin expression
Po Zhao (2019)
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.
S. Novello (2016)
High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer
A. Jääskeläinen (2018)
Anti-EpCAM antibodies for detection of metastatic carcinoma in effusions and peritoneal wash.
F. Carneiro (2019)
2015 update on the diagnosis and management of neoplastic pericardial disease
C. Lestuzzi (2015)
Immunocytochemical utility of claudin‐4 versus those of Ber‐EP4 and MOC‐31 in effusion cytology
T. Oda (2016)
The diagnostic role of BAP1 in serous effusions.
B. Davidson (2018)
An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin
A. Bellizzi (2020)
British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma
I. Woolhouse (2018)
Ancillary studies in pleural, pericardial, and peritoneal effusion cytology
K. Sundling (2018)